Alzheimer’s drug Bapineuzumab fails in second Phase 3 clinical trial

A second Phase 3 clinical trial of the drug bapineuzumab did not show benefits on tests of cognition and function in people with mild-to-moderate Alzheimer’s disease. As a result, all ongoing studies with the drug, intended to break up beta amyloid protein plaques, will be discontinued. Although the results of bapineuzumab trial have been disappointing, setbacks provide critical information to the research community for application in future studies.
Read the article >>

http://abcnews.go.com/Health/AlzheimersNews/research-halted-major-alzheimers-drug/story?id=16946503